Saturday 17 October 2026
Export TVGN’s income statement to Excel — free account
Tevogen Inc.
TVGN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 1.33%, free cash flow grew 5.78% and total debt rose 45.5%, each against the same quarter a year earlier.
7.07
0.01
−0.14%
Follow TVGN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 487.50 | 510.00 | 12.80 | 14.95 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 518.75 | 601.50 | 1,054.50 | 96.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 17 | 18 | 18 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | 0 | 4 | (60) | (14) | (26) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | — | 0 | 4 | (60) | (14) | (26) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | (0.11) | 16.41 | (122.17) | (4.68) | (8.08) | |||||
| Cash flow | — | — | — | — | — | (2.98) | (0.80) | (16.51) | (4.09) | (3.71) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (0.27) | 0.00 | (0.02) | |||||
| Free cash flow | — | — | — | — | — | (2.98) | (0.80) | (16.78) | (4.09) | (3.73) | |||||
| Book value | — | — | — | — | — | (59.36) | (55.02) | (190.77) | (2.28) | (2.48) | |||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 3 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | 0 | (8) | (12) | (12) | ||||
| Capex | — | — | — | — | — | — | — | 0 | — | 0 | |||||
| Free cash flow | — | — | — | — | — | (1) | 0 | (8) | (12) | (12) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | 0 | (84) | (7) | (6) | ||||
| Total debt | — | — | — | — | — | — | — | 14 | 1 | 4 | |||||
| Net debt | — | — | — | — | — | 0 | 0 | 13 | 0 | 4 | |||||
| Shareholders’ equity | — | — | — | — | — | (14) | (15) | (94) | (7) | (8) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (0.02) | 1.24 | (33.35) | (229.14) | (683.91) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | (30.39) | 110.75 | 18.70 | 165.04 | |||||
Negative figures in brackets.
Charts ten years each
Tevogen Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics Inc. | $47.8M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IBIO iBio, Inc. | $47.6M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLNN Clene Inc. | $47.0M | — (loss-making) | — (loss-making) | +233.33% (above 0%: growing) | n/m | +45.43% (above 0%: growing) | 60.00% | (5,941.11%) | Compare |
| TVGN Tevogen Inc. | $46.1M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | |
| INMB INmune Bio, Inc. | $45.8M | — (loss-making) | — (loss-making) | +8.70% (above 0%: growing) | n/m | +55.39% (above 0%: growing) | 100.00% | 0.00% | Compare |
| IMA ImageneBio, Inc. | $45.7M | — (loss-making) | — (loss-making) | −60.08% (below 0%: shrinking) | n/m | +23.76% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SER Serina Therapeutics, Inc. | $45.5M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $44.8M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $44.5M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $45.8M | — | — | +100.00% | — | +17.84% | 100.00% | 0.00% |
Tevogen Inc. (TVGN) key facts
- Tevogen Inc. (TVGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TVGN traded at $7.07, a market capitalization of $46.1 million.
- Return on equity was 165.0% and debt-to-equity -0.72.
Tevogen Inc. (TVGN) Latest News
No news at this impact. Lower the threshold for more.